Voyageur Acquires Exclusive Iodine Tech, Eyes Market Leadership

Voyageur Pharmaceuticals Ltd., a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, has made a significant strategic move by acquiring 100% ownership of an innovative iodine extraction technology known as the "Mueller Process." This proprietary technology was developed by Dr. Brian Mueller, who has been appointed as the Company's Director of Chemistry. The acquisition, which involved a lump sum cash payment and a running royalty on net sales, grants Voyageur exclusive intellectual property rights to advance its iodine extraction projects with enhanced cost efficiency, operational flexibility, and long-term supply-chain security. Initial bench-scale testing of the Mueller Process on brine water from the Anadarko and West Texas Basins has shown promising results, including greater than 90% yield to technical grade iodine and conversion to 99.5% pure iodine, all while being environmentally friendly with no volatile organic compounds or hazardous emissions.

Brent Willis, CEO & President of Voyageur, emphasized the strategic importance of this acquisition, highlighting its potential to enable the Company to produce iodine flake efficiently and possibly bypass the flake process entirely through its proprietary Streamlined API process. This could position Voyageur to achieve one of the lowest cost structures in the multi-billion-dollar iodine contrast drug industry. Additionally, the technology opens the door to potential elemental mineral extraction from the Company's ULI claim block in the Paradox Basin, Utah, targeting minerals such as lithium, iodine, bromine, boron, magnesium, potassium, and sodium. The global contrast media market is projected to grow significantly, with the North American market alone estimated at $2.65 billion annually, underscoring the vast opportunity for Voyageur's innovations.

In a related update, Voyageur has terminated its collaboration with Altillion Inc., previously announced on June 23, 2025, though it appreciates Altillion's contributions. The Company's broader vision includes becoming the first vertically integrated player in the radiology contrast media drug market, controlling all primary input costs from sourcing raw materials to final production. With its Frances Creek barium sulphate project and the new Mueller Process, Voyageur aims to set new benchmarks for quality and cost efficiency in the industry, embodying its motto of "From the Earth to the Bottle." For more details, view the original release on www.newmediawire.com, where the full announcement is available.